Celgene (NASDAQ:CELG) has been given a $166.00 price target by analysts at Oppenheimer in a note issued to investors on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective indicates a potential upside of 58.04% from the stock’s previous close.
Several other research analysts also recently weighed in on the stock. Morgan Stanley downgraded shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a report on Thursday, October 5th. Sanford C. Bernstein downgraded shares of Celgene from an “outperform” rating to a “market perform” rating and set a $121.00 price objective on the stock. in a report on Wednesday. BTIG Research restated a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Cantor Fitzgerald restated a “hold” rating and set a $112.00 price objective on shares of Celgene in a report on Monday, October 30th. Finally, Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective on the stock in a report on Monday, October 23rd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $132.63.
Celgene (CELG) traded up $0.29 on Thursday, reaching $105.04. 2,699,449 shares of the company’s stock traded hands, compared to its average volume of 4,826,241. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene has a 1 year low of $94.55 and a 1 year high of $147.17. The firm has a market capitalization of $82,243.13, a P/E ratio of 24.95, a price-to-earnings-growth ratio of 0.81 and a beta of 1.78.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Counsel LLC NY boosted its position in Celgene by 0.4% during the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 6 shares during the period. Fort Pitt Capital Group LLC boosted its position in Celgene by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 11 shares during the period. Flagship Harbor Advisors LLC boosted its position in Celgene by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 18 shares during the period. Savant Capital LLC boosted its position in Celgene by 0.9% during the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 20 shares during the period. Finally, TCI Wealth Advisors Inc. boosted its position in Celgene by 0.9% during the second quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock worth $395,000 after purchasing an additional 26 shares during the period. Institutional investors own 79.74% of the company’s stock.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
